This perspective addresses how insurance markets might respond if the US Supreme Court sides with the plaintiffs in the King v. Burwell case. The case challenges the legality of premium and cost-sharing subsidies for low- and middle-income people buying insurance in states where the federal government rather than the state is operating the marketplace under the Affordable Care Act (ACA).
- view as grid
- view as list
New Kaiser Policy Insight and Issue Brief Examine Policy Implications and Legal Arguments in the U.S. Supreme Court’s King v. Burwell Case
With the Supreme Court set to hear oral arguments in King v. Burwell on March 4, a new Policy Insight from the Kaiser Family Foundation’s Larry Levitt and Gary Claxton explores the policy implications for consumers and insurance markets if the Court were to side with the plaintiffs in the…
In this column for The Wall Street Journal’s Think Tank, Drew Altman examines the potential impact if the Supreme Court rules in favor of the plaintiffs in the King v. Burwell case. Based on Congressional Budget Office estimates, Altman presents a new Kaiser Family Foundation analysis that shows that 13…
In his first 2015 column for The Wall Street Journal’s Think Tank, Drew Altman explains why this year, status quo for the Affordable Care Act is not an option and how the Supreme Court rules in King v. Burwell will determine its path.
In his first 2015 column for The Wall Street Journal’s Think Tank, Drew Altman explains why this year, status quo for the Affordable Care Act is not an option and how the Supreme Court rules in King v. Burwell will determine its path. All previous columns by Drew Altman are…
The Affordable Care Act’s requirement that most private health insurance plans provide contraceptive coverage has been the focus of ongoing litigation in the federal courts. In response to recent Supreme Court actions in the Hobby Lobby and College of Wheaton cases, the U.S. Department of Health and Human Services issued…
Given recent news about some high-cost prescription drugs and the debate about who should pay for them, this month’s Kaiser Health Tracking Poll has a special focus on the issue. Nearly three-quarters of the public think that the cost of prescription drugs is unreasonable. Americans place much of the blame with the drug companies saying they set prices too high and that company profits are a major factor in drug pricing. The poll also finds that most of the public still hasn’t heard much about the Supreme Court case on whether people in states with federal marketplaces are eligible for financial assistance to purchase health insurance. Most feel that Congress and states should act if the Court rules for the plaintiffs, but there is no agreement among partisans.
With a Supreme Court decision on King v. Burwell looming, this Drew Altman column for The Wall Street Journal’s Think Tank plays out the politics of a ruling for the two major parties.
With the Supreme Court ruling on King v. Burwell upholding the Affordable Care Act’s federal subsidies, Drew Altman’s column in The Wall Street Journal’s Think Tank explores what the decision means and what’s next for the health law.
The latest Kaiser Health Tracking Poll finds that when told that the U.S. Supreme Court ruled to keep the Affordable Care Act (ACA) as it is, allowing subsidies to be provided to low- and moderate-income people in all states regardless of who runs their Marketplace, about 6 in 10 say they approve of the decision while about a third disapprove. The King v. Burwell ruling does not appear to have had an immediate effect on the public’s overall views of the health law. Still, most Americans do not think the ACA has cleared its last big hurdle with the June 25 Supreme Court ruling; just 18 percent think the King v. Burwell case was the last major battle over the ACA, while nearly 8 in 10 think there will be more to come.